Send to

Choose Destination
Brain Circ. 2016 Jan-Mar;2(1):28-47. doi: 10.4103/2394-8108.178546. Epub 2016 Mar 11.

Biomarkers for acute diagnosis and management of stroke in neurointensive care units.

Author information

Department of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida, USA.
Center for Translational Research in Neurodegenerative Disease, University of Florida College of Medicine, Gainesville, Florida, USA.
Banyan Biomarkers, Inc., Alachua, Florida, USA.


The effectiveness of current management of critically ill stroke patients depends on rapid assessment of the type of stroke, ischemic or hemorrhagic, and on a patient's general clinical status. Thrombolytic therapy with recombinant tissue plasminogen activator (r-tPA) is the only effective treatment for ischemic stroke approved by the Food and Drug Administration (FDA), whereas no treatment has been shown to be effective for hemorrhagic stroke. Furthermore, a narrow therapeutic window and fear of precipitating intracranial hemorrhage by administering r-tPA cause many clinicians to avoid using this treatment. Thus, rapid and objective assessments of stroke type at admission would increase the number of patients with ischemic stroke receiving r-tPA treatment and thereby, improve outcome for many additional stroke patients. Considerable literature suggests that brain-specific protein biomarkers of glial [i.e. S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP)] and neuronal cells [e.g., ubiquitin C-terminal hydrolase-L1 (UCH-L1), neuron-specific enolase (NSE), ╬▒II-spectrin breakdown products SBDP120, SBDP145, and SBDP150, myelin basic protein (MBP), neurofilament light chain (NF-L), tau protein, visinin-like protein-1 (VLP 1), NR2 peptide] injury that could be detected in the cerebrospinal fluid (CSF) and peripheral blood might provide valuable and timely diagnostic information for stroke necessary to make prompt management and decisions, especially when the time of stroke onset cannot be determined. This information could include injury severity, prognosis of short-term and long-term outcomes, and discrimination of ischemic or hemorrhagic stroke. This chapter reviews the current status of the development of biomarker-based diagnosis of stroke and its potential application to improve stroke care.


Biomarker; blood; cerebrospinal fluid (CSF); clinical trial; intracerebral hemorrhage (ICH); ischemic stroke; serum; transient ischemic attacks (TIAs)

Conflict of interest statement

Ronald L Hayes owns stock, receives compensation from, and is an executive officer of Banyan Biomarkers, Inc. and, as such, may benefit financially as a result of the outcomes of this research or work reported in this publication.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center